Moderna, Inc. (ETR:0QF)

Germany flag Germany · Delayed Price · Currency is EUR
23.81
-2.64 (-9.97%)
At close: Aug 1, 2025, 5:30 PM CET
-9.97%
Market Cap9.25B
Revenue (ttm)2.62B
Net Income (ttm)-2.47B
Shares Outn/a
EPS (ttm)-6.41
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,185
Average Volume992
Open26.14
Previous Close26.44
Day's Range23.28 - 26.54
52-Week Range20.18 - 110.94
Beta1.85
RSI38.56
Earnings DateJul 31, 2025

About Instructure Holdings

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Deutsche Börse Xetra
Ticker Symbol 0QF
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial Statements

News

UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.This decision affirms the ...

1 day ago - Wallstreet:Online

UK Court of Appeal Confirms Moderna's EP'949 Patent is Valid and Infringed by Pfizer/BioNTech

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent. This decision affirms the...

1 day ago - Accesswire

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.

1 day ago - Reuters

Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Moderna, Inc. MRNA will release earnings results for the second quarter, after the closing bell on Friday, Aug. 1.

1 day ago - Benzinga

Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Moderna, Inc. (NASDAQ: MRNA) will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1 . Analysts expect the Cambridge, Massachusetts-based company to report qua...

1 day ago - Benzinga

Moderna's Earnings: A Preview

Moderna (NASDAQ: MRNA) is preparing to release its quarterly earnings on Friday, 2025-08-01. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Mod...

2 days ago - Benzinga

More than 800 Moderna employees will lose their jobs this year as costs are slashed

Moderna announced a large layoff the day before the vaccine maker was set to release second-quarter results.

2 days ago - MarketWatch

Moderna to cut 10% of global workforce as Covid shot sales drop 20%

Moderna is reducing its global workforce by around 10% by the end of 2025 as demand for Covid-19 vaccines continues to weaken. The company, which had about 5,800 full-time employees across 18 countrie...

2 days ago - Invezz

Moderna plans to lay off 10% of workforce to cut costs

Moderna plans to trim roughly 10% of its global workforce by the end of the year to cut costs amid declining sales of its COVID-19 vaccines, the company said on Thursday.

2 days ago - Reuters

Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow

In a memo to employees, Moderna CEO Stephane Bancel said the company expects to have fewer than 5,000 workers by the end of the year.

2 days ago - CNBC

Pandemic darlings Moderna, BioNTech are now on two different paths

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find themselves on different paths.

2 days ago - CNBC

Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the C...

2 days ago - Wallstreet:Online

Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the C...

2 days ago - Accesswire

Moderna Announces Data to be Presented at ESMO Congress 2025

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2...

5 days ago - Wallstreet:Online

Moderna Announces Data to be Presented at ESMO Congress 2025

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2...

5 days ago - Accesswire

Market Whales and Their Recent Bets on MRNA Options

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna . Looking at options history for Moderna (NASDAQ: MRNA) we detected 9 trades. If we consider the specifics of eac...

7 days ago - Benzinga

EU regulator backs Moderna's updated COVID vaccine

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the vaccine maker said on Friday.

7 days ago - Reuters

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1

Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / ACCESS Newswire / July 25, 2025 / M...

8 days ago - Wallstreet:Online

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1

Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / ACCESS Newswire / July 25, 2025 / M...

8 days ago - Accesswire

What's Going On With Moderna Stock Wednesday?

Moderna Inc.’s (NASDAQ: MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date. On Wednesday, the stock is trading around 7% higher. Notably, there is no ne...

9 days ago - Benzinga